In June of 2023, the United States Food and Drug Administration (FDA) approved the use of low dose colchicine as the first anti-inflammatory drug to treat atherosclerotic disease. Specifically, “LoDoCo 0.5 mg daily” was indicated to “reduce the risk of myocardial infarction, stroke, coronary revascularization and cardiovascular death in adult patients with established atherosclerotic disease and or with multiple risk factors for cardiovascular disease”. This labeling indication, based on hard evidence from cardiovascular outcome trials conducted among individuals receiving aggressive guideline directed medical care, should sound familiar to preventive cardiologists and general internists as it is virtually identical to current FDA labeling for statin therapy [1].
